Cadired 5

Commenti: 0

Cadired5 Monocolina k del riso rosso | cadigroup.euThe strength and the safety of non-drug therapy: Monacolin K to 5%
The monacolin k from red yeast rice helps to maintain normal levels of blood cholesterol
Food supplement with red rice, hawthorn, carnitine, astaxanthin, niacin and chrome

Package: 40 tablets 600 mg

Red Yeast Rice at 5% in Monacolin K

It is a natural substance used for thousands of years in China to achieve the desired cholesterol values. The recent literature has proved that the best results have been obtained with the administration of 10 mg/ per day of fermented red yeast rice, without any serious adverse effect (table 1), in fact the Ministry of Health has allowed the increasing of the daily administration of Monacolin K from 3 to 10 mgs.

Table 1
Comparison metanalysis among different preparations containing Monascus

Treatement Dosage
(mg, as lovastatin)
% ( decreasing or increasing vs basal values)
CT LDL HDL TG
Cholestin 4,8 -16 -22 0 -7
Placebo -2 -3 0 +2
Xuezhikang 10 -24 -28 8 -30
Placebo -6 -7 -7 -10
Zhibituo 9 -19 -5 17 -33
Placebo 5 0 -7 -16

In the mentioned works no case of serious adverse effect has been registered.
In the patients treated with Xuezhikang (10 mg of monacolin K) both the LDL levels (of the 28%), and the cardiac end-points (from 10,7% in the controls to 4,7% in the treated ones, the reduction has been of the 45%, meaningful at the P<0,001) have reduced; the experience has been interrupted after 5 years and half, seen the good benefit had after the treatment (2). Our red yeast rice guarantees a quantity of Citrinin (mycotoxins) lower than the safety levels (< 0,50 ppm).

L Carnitine

  • It positively influences the lipid metabolism, thus allowing the best use and proving the synergic action against hyperlipidemia with products as the red yeast rice. (3)
  • In addition to the cholesterol-lowering action, the L Carnitine prevents the development of the atherosclerothic lesions and decreases the myotoxicity caused by the use of the statins. (5)
  • It is particularly useful in the diabetics because it decreases the resistance to insulin, thus regulating the homeostasis of the glucose. (4)
  • Recent studies have proved the effectiveness of the Carnitine in reducing the Lp (a). (1)

Hawthorn (Crataegus Oxyacantha) (TCR)

The hawthorn extract has a positive inotrope action, because it improves the functions of the cardiovascular system. This action is generally due to the content of flavonoids (with particular reference to the oligomeric proanthocyanidins) that improve the integrity of the circulatory system.
Its action increases the blood flow towards the coronaries, thus improving the oxygen count and its use by the heart. Additionally, it reduces the release of the lactate dehydrogenase (index of the myocardial damage during the ischemia-reperfusion) and this means that there is a protection of the cardiac muscle (VV AA). It has then be proved, on rats fed with a lipid-increasing diet, that the hawthorn extract prevents the increasing of the plasmatic lipids (table 2). Furthermore, it regulates the hepatic receptors of the LDL (table 3), in order to have a major afflux of the plasmatic LDL in the liver, of which it prevents the accumulation by increasing the cholesterol degradation up to bile acids, increasing the bile flow and decreasing the biosynthesis of the cholesterol. (6)

Table 2
Effect of TCR on body weight gain, plasma total cholesterol, lipoprotein cholesterol and atherogenic index (LDL + VLDL cholesterol/HDL cholesterol)

Parameters Group I Group II Group III
Body weight gain (g/6 weeks) 46,5 ± 9,7 50,1 ± 6,9 55,6 ± 10,1
Plasma total cholesterol (mg/dl) 83,7 ± 6,6 129,8 ± 7,8*** 94,6 ± 7,9##
LDL – cholesterol (mg/dl) 30,9 ± 3,1 62,2 ± 3,7*** 39,1 ± 5,4###
VLDL – cholesterol (mg/dl) 7,8 ± 1,0 23,1 ± 2,9*** 17,5 ± 5,4###
HDL – cholesterol (mg/dl) 42,6 ± 3,1 47,5 ± 5,3*** 46,6 ± 4,4###
Atherogenic index 0,88 ± 0,07 1,58 ± 0,20*** 0,97 ± 0,09###

Group I rats were fed normal rat chow. Groups II and III were fed the atherogenic diet. Group III rats were treated simultaneously with TCR (0.5 ml/100 g body weight per day) for 6 weeks. Group II was compared with group I – ***P < 0.001 Group III was compared with group II - # # P < 0.01, # # # P < 0.001 Table 3
Effect of TCR on liver total cholesterol, liver cholesterol biosynthesis, hepatic and fecal bile acids

Parameters Group I Group II Group III
Liver total cholesterol (mg/g) 5,5 ± 0,5 18,8 ± 1,1*** 9,3 ± 1,4###
Liver bile acids (mg/g)
Cholic acid
Deoxycholic acid

13,9 ± 1,4
5,7 ± 0,3

17,5 ± 1,6***
8,1 ± 0,6***

25,5 ± 2,9###
10,2 ± 1,0###
Liver cholesterol biosynthesis (cpm/g) 997,6 ± 109,2 470,2 ± 75,0** 316,5 ± 66,6###
Fecal bile acids (mg/day per rat)
Cholic acid
Deoxycholic acid

12,5 ± 1,2
11,8 ± 1,4

22,8 ± 2,3***
28,3 ± 2,4***

50,9 ± 6,0###
41,4 ± 5,1###

Group I rats were fed normal rat chow. Group II and III were fed the atherogenic diet. Group III rats were treated simultaneously with TCR (0.5 ml/100 g body weight per day) for 6 weeks. Cpm, counts per minute. Group II was compared with group I – ***P < 0.001 Group III was compared with group II - # # P < 0.01, # # # P < 0.001 Hawthorn has also a moderate antihypertensive action, both at a diastolic and systolic level, something which does not happen in the normotensive patients; this action is the result of different pharmacological actions, as the coronary vasodilator one, the inhibition of the ACE, the positive inotrope action and a light diuretic action.

Niacin – Chromium Picolinate

Numerous experimentations have proved that the trivalent chromium may let hyperlipedemias regress. The key factor for the action of Chrome may be an increased action of the insulin; in fact the shortage of Chrome may lead to the resistance against the insulin which goes to let the risk factors for the hyperlipedemia and the CVD increase. The combination with the trivalent Chrome allows to Niacin to act as lipid-lowering at very low dosages, thus allowing long treatments without any adverse effect. It is finally to remember that niacin as a good effectiveness against a LP excess (a), that appears among the various atherogenic in individuals that have particular genes. (1)

Astaxantin

It is a natural antioxidant, ten times more powerful than the Beta-carotene and one hundred times more than the vitamin E; it is useful to challenge the oxidative stress in the hyperlipidemic patient.

Indications

Useful for the reduction of total cholesterol and LDL cholesterol and the maintenance of the obtained values.
​It can also increase the levels of HDL cholesterol and lowering triglycerides.
Do not use in case of treatment with other lipid-lowering drugs, when pregnant or during lactation.
Nutritional Information for 2 tablets

  • L-Carnitine Tartrate – 650 mg
  • Red rice yeast dry extract – 200 mg
  • Equivalent to Monacolin K – 10 mg
  • Hawthorn dry extract – 200 mg
  • equivalent to Vitexin – 3,6 mg
  • Niacin – 30 mg (187,5% of RDA)
  • Hematococcus Pluvialis powder – 2 mg
  • equivalent to Astaxantin – 100 mcg
  • Chromium polynicotinate – 1,6 mg
  • equivalent to Chromium – 200 mcg (500% of RDA)

How to use

Take 1 or 2 tablets per day, one preferably in the evening.
Do not use in case of treatment with other lipid-lowering drugs, when pregnant or during lactation.

Bibliography

  1. Clarke R., et al., “Genetic variants associated with Lp(a) lipoprotein level and coronary disease”, The New England Journal of Medicine, 2009, 361, 26, pp. 2518-2528;
  2. Jianping Liu, Jing Zhang, Yi Shi, Sameline Grimsgaard, Terje Alraek, Vinjar Fonnebo (2006), “Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials”, Chinese Medicine, 2006, I:4;
  3. Noland Robert C., Koves Timothy R., Seiler Sarah E., Lum Helen, Lust Robert M., Ilkayeva Olga, Stevens Robert D., Hegardt Fausto G., Muoio Deborah M. (2009), “Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control”, Journal of biological chemistry, 284, 34, August 21, pp.22840-22852;
  4. Power R. A., Hulver M. V., Zhang J. Y., Dubois J., Marchand R. M., Ilkayeva O., Muoio D. M., Mynatt R. L. (2007), “Carnitine revisited: potential use as adjunctive treatment in diabetes”, Diabetologia, 50: pp.824-832;
  5. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N (2001), “L-Carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits.”, Pharmacol Res., Sep, 44 (3): pp. 235-42;
  6. Shanti Rajendran, P. D. Deepalakshmi, K. Parasakthy, H. Devaraj, S. Niranjali Devaraj, Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet, Atherosclerosis 123, 1996, pp. 235-241

Leave a Reply

Your email address will not be published. Required fields are marked *